IBD barriers across the continents: a continent-specific analysis - Australasia.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The authors do not perceive there to be any conflicts of interest. Of note, Dr Alexander Elford (corresponding author) is supported by the Australian Commonwealth government via a Research Training Program Scholarship. Professor Rupert Leong has received advisory board fees from AbbVie, Aspen, BMS, Celgene, Celltrion, Chiesi, Ferring, Glutagen, Hospira, Janssen, Lilly, MSD, Novartis, Pfizer, Prometheus Biosciences, Takeda. Research grants from Celltrion, Shire, Janssen, Takeda, Joanna Tiddy grant from University of Sydney, Gastroenterological Society of Australia, NHMRC, Gutsy Group, Pfizer. Associate Professor Christensen has received speaking fees from Abbvie, Janssen, Pfizer, Takeda and Ferring; research grants from Janssen and Ferring Pharmaceuticals and served on the advisory board of Gilead and Novartis."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."